These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38581435)

  • 41. Predicting Visual Acuity Responses to Anti-VEGF Treatment in the Comparison of Age-related Macular Degeneration Treatments Trials Using Machine Learning.
    Chandra RS; Ying GS
    Ophthalmol Retina; 2024 May; 8(5):419-430. PubMed ID: 38008218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
    Sakurada Y; Nakamura Y; Yoneyama S; Mabuchi F; Gotoh T; Tateno Y; Sugiyama A; Kubota T; Iijima H
    Ophthalmic Res; 2015; 53(1):2-7. PubMed ID: 25472810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predicting Incremental and Future Visual Change in Neovascular Age-Related Macular Degeneration Using Deep Learning.
    Fu DJ; Faes L; Wagner SK; Moraes G; Chopra R; Patel PJ; Balaskas K; Keenan TDL; Bachmann LM; Keane PA
    Ophthalmol Retina; 2021 Nov; 5(11):1074-1084. PubMed ID: 33516917
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Kanadani TCM; Veloso CE; Nehemy MB
    Ophthalmologica; 2018; 240(4):200-207. PubMed ID: 29768266
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration.
    García-Quintanilla L; Almuiña-Varela P; Maroñas O; Gil-Rodriguez A; Rodríguez-Cid MJ; Gil-Martinez M; Abraldes MJ; Gómez-Ulla de Irazazabal F; González-Barcia M; Mondelo-Garcia C; Cruz R; Estany-Gestal A; Fernández-Rodríguez M; Fernández-Ferreiro A
    Invest Ophthalmol Vis Sci; 2023 Oct; 64(13):34. PubMed ID: 37862026
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outer retinal tubulations response to anti-VEGF treatment.
    Espina M; Arcinue CA; Ma F; Camacho N; Barteselli G; Mendoza N; Ferrara N; Freeman WR
    Br J Ophthalmol; 2016 Jun; 100(6):819-23. PubMed ID: 26423451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
    Inan S; Baysal Z; Inan UU
    Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
    [No Abstract]   [Full Text] [Related]  

  • 49. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).
    Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K
    Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Cho HJ; Park SM; Kim J; Nah SK; Lee J; Lee DW; Kim JW
    Acta Ophthalmol; 2021 Jun; 99(4):e540-e546. PubMed ID: 32996674
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
    Medina FMC; Motta AALD; Takahashi WY; Carricondo PC; Motta MMDS; Melo MB; Vasconcellos JPC
    Ophthalmic Res; 2019; 61(3):168-173. PubMed ID: 28641277
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Impact of Epiretinal Membrane in Neovascular Age-Related Macular Degeneration Treatment: A Spectral-Domain Optical Coherence Tomography Study.
    Chatziralli I; Stavrakas P; Theodossiadis G; Ananikas K; Dimitriou E; Theodossiadis P
    Semin Ophthalmol; 2018; 33(5):651-656. PubMed ID: 29115893
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.
    Cobos E; Recalde S; Anter J; Hernandez-Sanchez M; Barreales C; Olavarrieta L; Valverde A; Suarez-Figueroa M; Cruz F; Abraldes M; Pérez-Pérez J; Fernández-Robredo P; Arias L; García-Layana A
    Acta Ophthalmol; 2018 Mar; 96(2):e201-e212. PubMed ID: 28926193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Responses of Types 1 and 2 Neovascularization in Age-Related Macular Degeneration to Anti-Vascular Endothelial Growth Factor Treatment: Optical Coherence Tomography Angiography Analysis.
    Kim JM; Cho HJ; Kim Y; Jung SH; Lee DW; Kim JW
    Semin Ophthalmol; 2019; 34(3):168-176. PubMed ID: 31132283
    [No Abstract]   [Full Text] [Related]  

  • 55. PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Do DV; Rhoades W; Nguyen QD
    Retina; 2020 Apr; 40(4):643-647. PubMed ID: 31145389
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
    Wykoff CC; Brown DM; Maldonado ME; Croft DE
    Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
    Fung AT; Kumar N; Vance SK; Slakter JS; Klancnik JM; Spaide RS; Freund KB
    Eye (Lond); 2012 Sep; 26(9):1181-7. PubMed ID: 22878451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive findings of visual outcome in spectral domain optical coherence tomography after ranibizumab treatment in age-related macular degeneration.
    Kwon YH; Lee DK; Kim HE; Kwon OW
    Korean J Ophthalmol; 2014 Oct; 28(5):386-92. PubMed ID: 25276080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential Circulating MicroRNA Expression in Age-Related Macular Degeneration.
    ElShelmani H; Brennan I; Kelly DJ; Keegan D
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.